logo

For the Inventor, By the Inventor

Edison, NJ, United States of America

Hong Zhao

This inventor holds 36 USPTO granted patents and 17 published patent applications and 7 EPO patents, primarily in Polymeric Drug Delivery. Top assignees: Enzon Pharmaceuticals, Inc., Enzon, Inc., Belrose Pharma, Inc.. Active years: 1999-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hong Zhao. Retrieved from https://idiyas.com/inventor/hong-zhao-7msvssso

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 36 

% Patents Active = 16.7

 

Average Co-Inventor Count = 2.1

ph-index = 13

Forward Citations = 694(Granted Patents)


Location History:

  • Piscataway, NJ (US) (1999 - 2001)
  • Edison, NJ (US) (2003 - 2013)

Company Filing History:

goldMedal25 out of 52 
 
Enzon Pharmaceuticals, Inc.
 patents
silverMedal10 out of 100 
 
Enzon, Inc.
 patents
bronzeMedal1 out of 1 
 
Belrose Pharma, Inc.
 patent

Years Active: 1999-2013

Loading Chart...
Loading Chart...
Areas of Expertise:
Polymeric Bioconjugates
Targeted Prodrugs
Multi-Arm Conjugates
Biodegradable Linkers
Oligonucleotide Delivery
Cancer Treatment
Polyalkylene Oxides
Hydrolysis Resistant Linkages
Amino Acid Derivatives
Camptothecin Derivatives
Vancomycin Prodrugs
Stereoselective Acylation
36 patents (USPTO):Explore Patents
1. 8618124 - Heterobifunctional polymeric bioconjugates (2013-12-31),
2. 8367065 - Targeted polymeric prodrugs containing multifunctional linkers (2013-02-05),
3. 8299089 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers (2012-10-30),
4. 8268318 - Polyalkylene oxides having hindered ester-based biodegradable linkers (2012-09-18),
5. 8192743 - Releasable polymeric conjugates based on aliphatic biodegradable linkers (2012-06-05),
6. 8168605 - Polymeric oligonucleotide prodrugs (2012-05-01),
7. 8133707 - Methods of preparing activated polymers having alpha nitrogen groups (2012-03-13),
8. 8110559 - Hindered ester-based biodegradable linkers for oligonucleotide delivery (2012-02-07),
9. 7989554 - Reacting polyalkylene oxide with base, tertiary alkyl haloacetate, then acid to prepare polyalkylene oxide carboxylic acid (2011-08-02),
10. 7928095 - Treatment of resistant or refractory cancers with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin (2011-04-19),
11. 7897647 - Releasable polymeric conjugates based on aliphatic biodegradable linkers (2011-03-01),
12. 7868131 - Methods of preparing polymers having terminal amine groups (2011-01-11),
13. 7723351 - Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers (2010-05-25),
14. 7625898 - Posaconazole polymer conjugates and methods of treatment using posaconazole and polymer conjugates thereof (2009-12-01),
15. 7601798 - Methods of preparing polymers having terminal amine groups using protected amine salts (2009-10-13),

Title: Innovations of Hong Zhao in Bioconjugate Technology

Introduction

Hong Zhao, based in Edison, NJ, is an accomplished inventor with an impressive portfolio of 36 patents. His work predominantly focuses on the development of novel polymeric systems for delivering biologically active compounds, bridging the gap between chemistry and medicine.

Latest Patents

Zhao's latest patents showcase his innovative approach to bioconjugate technology. One of his significant patents involves heterobifunctional polymeric bioconjugates designed as prodrug platforms for delivering biologically active compounds, such as proteins and monoclonal antibodies. This patent details methods of making and utilizing these compounds, which hold great promise for therapeutic applications. Another noteworthy invention is centered around targeted polymeric prodrugs that feature multifunctional linkers. This invention outlines the creation of single chain antibody-directed polymeric prodrugs and provides methodologies for utilizing these polymeric delivery systems in treating mammals.

Career Highlights

Throughout his career, Hong Zhao has made substantial contributions while working with reputable companies in the pharmaceutical industry, including Enzon Pharmaceuticals and Enzon, Inc. His work at these institutions has cemented his reputation as a leading innovator in the field of bioconjugate technology.

Collaborations

Zhao has collaborated with notable experts in the field, including Richard B Greenwald and Annapurna Pendri. These collaborations have facilitated the advancement of his research and the successful development of new inventions, enhancing the capabilities of therapeutic treatments available today.

Conclusion

Hong Zhao's contributions to biotechnology through his patents are remarkable and signify the continued progress in the delivery of biologically active compounds. With 36 patents to his name, Zhao's innovations not only contribute significantly to his field but also hold the potential to impact medical treatments and enhance patient care in the future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…